Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company that focuses on selling and marketing products to community-based primary care physicians. The company currently has two products in the market Antara and Factive. Antara (fenofibrate) capsule is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. Factive (gemifloxacin mesylate) tablet is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Besides this, Oscient has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).
In 2006, Oscient earned $46.2 million in revenue, 82.7% of which came from product sales. Other revenues, consisting primarily of sublicensing revenues related to Factive, accounted for the balance 17.3%. Based on preliminary results, the company expects to post total revenues of approximately $80 million in 2007, representing 73% y-o-y growth. Headquartered in Waltham, Massachusetts, Oscient employs 336 people.